List of Excipients in Branded Drug LEVONORGESTREL AND ETHINYL ESTRADIOL

« Back to Dashboard

Generic Drugs Containing LEVONORGESTREL AND ETHINYL ESTRADIOL

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	levonorgestrel and ethinyl estradiol	0591-0295	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	levonorgestrel and ethinyl estradiol	0591-0295	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	levonorgestrel and ethinyl estradiol	0591-0295	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in LEVONORGESTREL AND ETHINYL ESTRADIOL?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED

Levonorgestrel and Ethinyl Estradiol Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Levonorgestrel and ethinyl estradiol is a mature, highly competitive oral contraceptive combination with limited core patent protection and substantial generic supply. Commercial value depends on manufacturing efficiency, tablet robustness, packaging, regimen design, tolerability, and access rather than on novel active-ingredient exclusivity. The strongest excipient opportunities are low-dose content uniformity, rapid and reliable dissolution, moisture protection, compact 28-day packaging, and differentiated extended-cycle or chewable presentations.

What is the market status of levonorgestrel and ethinyl estradiol?

Levonorgestrel and ethinyl estradiol is an estrogen-progestin combination marketed in multiple strengths and dosing regimens. Common products contain:

Product type	Levonorgestrel	Ethinyl estradiol	Typical regimen
Standard low-dose tablet	0.10 mg	0.02 mg	21 active tablets plus placebo or tablet-free interval
Standard tablet	0.15 mg	0.03 mg	21 active tablets plus placebo or tablet-free interval
Extended-cycle product	0.15 mg	0.03 mg	84 active tablets plus seven inactive or low-estrogen tablets
Chewable product	0.1 mg	0.02 mg	24 active tablets plus four inactive tablets

Brand and generic examples have included Alesse, Aviane, Lessina, Levora, Nordette, Seasonale, Seasonique, Amethia, Kurvelo and equivalent products. Exact strengths, inactive ingredients, packaging and availability vary by manufacturer and market. FDA-approved products are listed in FDA’s Drugs@FDA and Orange Book databases (U.S. Food and Drug Administration [FDA], n.d.-a, n.d.-b).

The active ingredients are small molecules, not biologics. Biosimilar competition is therefore not relevant. Competition occurs through abbreviated new drug applications, product-specific pharmaceutical equivalence, bioequivalence, manufacturing economics and distribution.

What patents protect levonorgestrel and ethinyl estradiol products?

The original composition-of-matter patents for levonorgestrel and ethinyl estradiol contraceptive products are generally expired or no longer commercially significant in the United States. The principal barriers are now product development, regulatory compliance, manufacturing scale and market access.

IP category	Current commercial relevance
Active-ingredient patents	Low for standard combinations; historical patents are generally expired
Basic tablet-composition patents	Low unless tied to a specific formulation or delivery system
Extended-cycle regimen patents	Historically relevant, but many claims have expired or have limited remaining value
Chewable or orally disintegrating formulations	Potentially relevant where a specific composition, process or use claim remains enforceable
Packaging and calendar-dosing systems	Usually secondary protection and often vulnerable to design-around
Method-of-use patents	May cover contraceptive regimens or noncontraceptive benefits, subject to claim scope and expiration
Manufacturing-process patents	Can protect impurity control, particle engineering, blending, coating or continuous processing
Trademark and trade dress	Often more commercially important than patent exclusivity for mature brands

A complete live patent opinion requires a product-specific review of FDA Orange Book listings, United States Patent and Trademark Office records, international registers and litigation dockets. Standard levonorgestrel and ethinyl estradiol tablets should be treated as low patent-barrier products unless a specific branded formulation has a live listed patent or enforceable nonlisted process rights.

When does levonorgestrel and ethinyl estradiol lose exclusivity?

For standard generic versions, the core exclusivity period has already ended in the United States. Generic entry has occurred across multiple strengths and regimens. The relevant commercial question is not whether basic generic entry is legally possible, but whether a new product can achieve a lower cost of goods, a differentiated presentation or preferred formulary status.

FDA approval pathways include:

• ANDA approval for pharmaceutical-equivalent tablets with demonstrated bioequivalence.
• 505(b)(2) approval for modified dosage forms, alternative regimens, different delivery systems or other changes not fully covered by an ANDA.
• NDA approval for a new branded formulation or combination with clinically meaningful differentiation.

Paragraph IV litigation is generally most relevant when a sponsor challenges a live Orange Book-listed patent for a specific branded product. For mature standard tablets, the commercial risk from Paragraph IV litigation is usually lower than the risk of price erosion after multiple generic entrants. A new formulation sponsor should still assess whether its product will have Orange Book-listed patents and whether those patents are likely to withstand obviousness, written-description and enablement challenges under the Hatch-Waxman framework.

What excipients are used in levonorgestrel and ethinyl estradiol tablets?

Commercial products use conventional oral solid dosage excipients. The exact composition differs by manufacturer and should be confirmed against the current DailyMed label or approved product documentation.

Excipient function	Common candidate materials	Primary development objective
Diluent	Lactose, microcrystalline cellulose, starch, dibasic calcium phosphate	Achieve tablet mass and blend uniformity
Binder	Povidone, copovidone, hydroxypropyl cellulose, pregelatinized starch	Improve granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Support rapid breakup and dissolution
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Control ejection force and sticking
Glidant	Colloidal silicon dioxide, talc	Improve flow and die filling
Film former	Hypromellose, polyvinyl alcohol	Protect the tablet and improve handling
Plasticizer	Polyethylene glycol, triacetin	Improve coating flexibility
Colorant	Iron oxides, titanium dioxide where permitted, approved lake colors	Product identification and regimen differentiation
Sweetener and flavor	Sucralose, aspartame, mannitol, flavors	Improve chewable acceptability
Surfactant or wetting agent	Sodium lauryl sulfate, polysorbates	Support wetting of low-dose active particles

DailyMed listings show that inactive ingredients vary materially between manufacturers even where the active ingredients and strengths are the same (National Library of Medicine, n.d.). That variation creates room for formulation design, but it does not automatically create meaningful clinical or patent differentiation.

How should excipient selection address low-dose content uniformity?

Content uniformity is the central technical issue. A typical tablet may contain only 20 to 30 micrograms of ethinyl estradiol and 100 to 150 micrograms of levonorgestrel. The active ingredients represent a small fraction of total tablet mass, which increases the risk of segregation, assay variability and blend sampling error.

A robust strategy should include:

1. Pre-blending or carrier-based dilution of each hormone.
2. Controlled particle-size distribution for both actives and the principal diluent.
3. Low-shear blending that limits segregation after lubrication.
4. Validated blend uniformity sampling based on the actual equipment geometry.
5. In-process control of tablet weight, hardness, friability and assay.
6. A dissolution method that can detect formulation drift at low drug loadings.

Direct compression can reduce processing steps and cost, but it requires excellent powder flow and segregation control. Wet granulation can improve uniformity and compressibility, but moisture and heat exposure must be controlled. Dry granulation may provide a useful balance where the active ingredients or excipient system are sensitive to water.

What formulation strategy offers the strongest commercial opportunity?

The strongest opportunities are differentiated products that improve manufacturing or adherence without changing the therapeutic premise.

Standard low-cost generic tablets

A standard immediate-release tablet has the largest volume opportunity but the lowest margin potential. The formulation should prioritize:

• Reliable low-dose uniformity.
• Fast disintegration.
• Low tablet weight.
• High-speed compression.
• Minimal sticking and picking.
• Low-cost, widely available excipients.
• Stable supply of colorants and coating materials.

An excipient system based on microcrystalline cellulose, lactose or dibasic calcium phosphate, crospovidone or croscarmellose sodium, magnesium stearate and a conventional film coat is commercially defensible when it provides robust process capability.

Extended-cycle regimens

Extended-cycle products reduce the number of withdrawal bleeds and require calendar packaging that minimizes dosing errors. The technical opportunity is less about a novel excipient and more about the interaction of:

• Long-term tablet stability.
• High-volume blister packaging.
• Distinct visual identification of active and inactive tablets.
• Moisture control during multi-month storage.
• Packaging that supports continuous dosing.

Blister materials, desiccant integration, foil selection and print durability can be as important as the tablet formula.

Chewable tablets

Chewable formulations offer differentiation through administration convenience, but they introduce difficult excipient tradeoffs. The product must balance:

• Hormone taste and odor masking.
• Acceptable mouthfeel.
• Adequate mechanical strength.
• Rapid dispersion after chewing.
• Low moisture uptake.
• Compatibility with sweeteners and flavors.
• Stability of the film coat or printed surface.

Mannitol, xylitol, microcrystalline cellulose, crospovidone, sweeteners and flavor systems may be considered. Aspartame may be unsuitable for some populations or labeling strategies because of phenylalanine-related labeling requirements. Sugar alcohols may create gastrointestinal tolerability concerns at higher quantities.

Orally disintegrating and rapidly dispersible tablets

An orally disintegrating presentation could support users who have difficulty swallowing conventional tablets. The low active dose is technically favorable, but the formulation must control moisture sensitivity, friability and dose uniformity. A 505(b)(2) strategy may be more appropriate than an ANDA if the dosage form, administration method or labeling differs materially from approved products.

How strong is the patent estate for excipient-based innovation?

An excipient alone rarely creates durable protection. Patent strength improves when the excipient is part of a clearly defined composition or process that produces measurable performance benefits.

More defensible claim structures may cover:

• A narrow ratio of diluent, binder and disintegrant that improves content uniformity.
• A specific particle-size distribution for hormone-containing granules.
• A low-moisture composition with defined impurity limits.
• A taste-masked chewable formulation with a defined dissolution profile.
• A coating system that protects the actives during extended storage.
• A manufacturing process that reduces degradation products or blend segregation.
• A calendar package combined with a defined dosing regimen.

Weak claim structures include broad claims to conventional excipients, routine film coating, ordinary tablet compression or a standard combination of known diluents and disintegrants. Obviousness risk is high where the formulation uses familiar excipients for their established functions.

What regulatory issues affect excipient strategy?

FDA review focuses on safety, quality, identity, strength, purity, bioavailability and bioequivalence. A new excipient or novel use level can create a larger regulatory burden than a conventional excipient with established oral use.

Key considerations include:

• FDA Inactive Ingredient Database precedent.
• Maximum potency and route-specific prior use.
• Genotoxic, reproductive, allergenic and impurity assessments.
• Residual solvents and elemental impurities.
• Compatibility with levonorgestrel and ethinyl estradiol.
• Dissolution under relevant pH conditions.
• Stability-indicating analytical methods.
• Packaging interaction and extractables and leachables.
• Labeling for phenylalanine, sugars, alcohols or other excipient-specific issues.

For a conventional immediate-release tablet, an ANDA is usually the most economical pathway. A novel chewable, orally disintegrating, extended-release or alternative-delivery product may require a 505(b)(2) application and a stronger clinical and regulatory justification.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are moderate rather than fundamental. Both hormones are established pharmaceutical substances, and conventional tableting infrastructure is widely available. The principal barriers are process control and scale.

The most important manufacturing risks are:

• Hormone segregation during transfer and compression.
• Assay variability at microgram-scale ethinyl estradiol loading.
• Cross-contamination in multiproduct facilities.
• Lubrication-related dissolution changes.
• Moisture-driven degradation.
• Coating variability across large tablet batches.
• Stability loss in high-humidity markets.
• Packaging defects that compromise calendar adherence.

Process patents may have value if they protect a demonstrated reduction in impurities, improved content uniformity or a scalable continuous process. Trade secrets involving blending order, equipment settings, in-process sampling and cleaning validation may provide greater practical protection than a broad formulation patent.

What licensing and partnership opportunities exist?

Licensing value is most credible in four areas:

1. A differentiated chewable or orally disintegrating formulation with bioequivalence support.
2. A proprietary manufacturing platform that improves low-dose uniformity or reduces batch failure.
3. A packaging and adherence system designed for extended-cycle regimens.
4. Regional commercialization rights in markets where branded contraceptive access remains fragmented.

A conventional tablet formula based on standard excipients is unlikely to command substantial licensing economics unless it provides a documented cost or quality advantage. Partnerships with contract development and manufacturing organizations can be attractive where the sponsor lacks low-dose hormonal handling capability, validated containment systems or specialized packaging capacity.

How does levonorgestrel and ethinyl estradiol compare with competing oral contraceptives?

Product category	Competitive position	Excipient opportunity
Levonorgestrel and ethinyl estradiol	Mature, low-cost, broad generic availability	Manufacturing efficiency and adherence packaging
Norgestimate and ethinyl estradiol	Mature generic combination	Similar tablet and packaging differentiation
Drospirenone and ethinyl estradiol	Higher-value branded and generic segments	Tolerability positioning and specialty formulations
Desogestrel and ethinyl estradiol	Generic competition varies by market	Regional regulatory and supply opportunities
Progestin-only oral contraceptives	Different clinical positioning	Swallowability, adherence and hormone-exposure differentiation
Long-acting reversible contraceptives	Higher procedure and device complexity	Excipient opportunity is limited compared with device or delivery technology

Levonorgestrel and ethinyl estradiol generally compete on price, availability, prescriber familiarity and packaging convenience. It is difficult for an excipient change alone to overcome the clinical and commercial advantages of a competing product with a different hormonal profile.

What generic launch scenarios are most likely?

Three launch scenarios are commercially realistic:

Low-cost standard generic

This approach targets wholesalers, pharmacy benefit managers and public procurement. It requires low cost of goods, reliable supply and broad regulatory coverage. Margin compression is likely after multiple entrants.

Differentiated adherence product

A chewable, calendar-packaged or extended-cycle product can support higher pricing if the sponsor obtains regulatory differentiation and secures pharmacy or payer access. The value depends on demonstrated patient preference and sufficient channel coverage.

Regional private-label product

A manufacturer can use an established formulation and package it for specific national markets, private-label distributors or public-sector tenders. Geographic regulatory strategy and supply reliability may matter more than patent protection.

What is the commercial outlook for levonorgestrel and ethinyl estradiol?

The commercial opportunity is strongest where the sponsor can combine a mature active-ingredient platform with one or more of the following:

• Lower tablet manufacturing cost.
• Better low-dose content uniformity.
• Improved humid-climate stability.
• More reliable high-speed compression.
• Chewable or swallowability-oriented dosage forms.
• Extended-cycle packaging.
• Private-label or regional distribution.
• Contract manufacturing for low-dose hormonal products.

A conventional formulation without measurable process or adherence benefits is likely to face rapid price competition. A defensible program should begin with target product profile definition, excipient compatibility screening, content-uniformity modeling, dissolution risk assessment, stability studies and a product-specific patent search.

Key Takeaways

• Levonorgestrel and ethinyl estradiol is a mature small-molecule combination with broad generic competition.
• Core active-ingredient patent protection is generally no longer the primary commercial barrier.
• Low-dose content uniformity is the central formulation challenge.
• Conventional excipients can support a low-cost generic, but they provide limited standalone patent value.
• Chewable, orally disintegrating and extended-cycle presentations offer greater differentiation.
• Packaging, moisture protection and calendar dosing can create commercial value comparable to the tablet formulation.
• A 505(b)(2) pathway may be more suitable for materially modified dosage forms.
• Manufacturing know-how, process controls and supply reliability may be more valuable than broad excipient claims.
• Biosimilar risk does not apply because the product contains small-molecule active ingredients.
• The best opportunity is a formulation or packaging platform tied to a measurable adherence, stability, quality or cost advantage.

FAQs

Can lactose be used in levonorgestrel and ethinyl estradiol tablets?

Yes. Lactose is a common oral tablet diluent, but compatibility, moisture exposure, particle size and supplier controls must be evaluated for the specific hormone blend.

Is a new excipient enough to obtain patent protection?

Usually not. Patent strength generally requires a defined composition, process or performance result that is not predictable from routine excipient selection.

Are levonorgestrel and ethinyl estradiol products eligible for biosimilar development?

No. Biosimilar pathways apply to biological products. These contraceptives are small-molecule drug products developed through generic or modified-drug pathways.

What excipient issue is most likely to cause a failed batch?

Blend segregation and assay variability are major risks because ethinyl estradiol and levonorgestrel are present at very low concentrations relative to tablet mass.

Can a chewable version obtain a higher price than a standard generic?

It can, but only if the sponsor establishes regulatory differentiation, acceptable taste and mouthfeel, reliable bioequivalence or a suitable 505(b)(2) basis, and commercial access through pharmacies or payers.

References

1. U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2022). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.